Magnera is expected to report consensus revenue of approximately $898.98 million and an adjusted EPS of $0.39 for the quarter ending September 30, with its current share price of $11.80 trading significantly below the average analyst target of $15.50. The primary focus for investors is the progress of the "Project CORE" integration following the 2024 merger of Glatfelter and Berry Global’s health division, specifically regarding synergy capture and debt reduction.
While the company delivered record adjusted EBITDA of $99 million in the preceding quarter, a wider GAAP net loss due to high interest expenses remains a point of caution. Management has reaffirmed a full-year free cash flow guidance of $90 million to $110 million, signaling confidence in the operational turnaround despite persistent raw material inflation.